Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 1;43(9):e53-e55.
doi: 10.1097/IAE.0000000000003853.

Correspondence

Affiliations
Comment

Correspondence

Fares Antaki et al. Retina. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply.
    Mathai M, Godwin KS, Albarracin J, Levinson J, Broderick K, Melamud A. Mathai M, et al. Retina. 2023 Sep 1;43(9):e55-e56. doi: 10.1097/IAE.0000000000003854. Retina. 2023. PMID: 37263183 No abstract available.

Comment on

References

    1. Mathai M, Godwin KS, Albarracin J, et al. 360 degree endolaser versus focal endolaser in primary rhegmatogenous retinal detachment repair. Retina 2022;42:2046–2050.
    1. Wang JC, Ryan EH, Ryan C, et al. Factors associated with the use of 360-degree laser retinopexy during primary vitrectomy with or without scleral buckle for rhegmatogenous retinal detachment and impact on surgical outcomes (pro study report number 4). Retina 2019;40:2070–2076.
    1. Dirani A, Antaki F, Rhéaume MA, et al. 360-degree intra-operative laser retinopexy for the prevention of retinal re-detachment in patients treated with primary pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2020;258:249–256.
    1. Soekamto C, Chu ER, Johnson DA, et al. Protective role of 360° laser retinopexy in patients with rhegmatogenous retinal detachment: a systematic review and meta-analysis. Korean J Ophthalmol 2021;35:215–222.
    1. Antaki F, Dirani A, Bachour K, et al. Comment on: localized versus 360° intraoperative laser retinopexy in cases of rhegmatogenous retinal detachment with mild-to-moderate grade proliferative vitreoretinopathy. Eye (Lond) 2021;35:3174–3175.

LinkOut - more resources